Compare DexCom, Inc. (DXCM) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Gemini Space Station Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Gemini Space Station Inc trades at $4.43 (market cap $579.55M). The key difference: DexCom, Inc. is far larger — about 55× Gemini Space Station Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Gemini Space Station Inc for 14 Days on average.
| DXCM | GEMI | |
|---|---|---|
Market Cap | $31.86B | $579.55M |
Volume | 3,607,070 | 1,882,406 |
Sector | Health | Financials |
52-Week High | $92.34 | $25.41 |
52-Week Low | $54.84 | $3.54 |
Typical Hold Time | 62 Days | 14 Days |
Enterprise Value | $31.32B | $558.57M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Gemini Space Station (GEMI) trades at $4.40, down 2% today amid bearish technical signals and persistent financial losses. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings expectations with a net loss of -$0.89 per share. Despite expanding services revenue and new product offerings, negative profit margins and cash flow challenges persist. Technical indicators show oversold conditions with RSI readings below 11, while moving averages signal continued downward pressure.
The stock faces significant fundamental headwinds with negative margins and cash burn, though analyst consensus suggests 19% upside to the $5.25 price target. Key risks include ongoing litigation, competitive pressures in financial services, and the company's ability to achieve profitability. Recent SEC approval for tokenized stock trading could provide growth opportunities if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
